InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
Go back to InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum| InferX Corporation (NASDAQ: IFRX) | Delayed: 2.12 +0.03 (1.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.09 | 52 Week High | $0.05 | |||
| Open | $2.11 | 52 Week Low | $0.00 | |||
| Day High | $2.19 | P/E | N/A | |||
| Day Low | $2.07 | EPS | $0.00 | |||
| Volume | 345,152 | |||||
